Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA, WHO Biosimilar Naming Proposals Take Shape

Executive Summary

FDA appears to be awaiting HHS clearance of its guidance, while WHO has released its proposal for public comment.


Related Content

Biosimilar Guidances Expected In ‘Near Future,’ But Unnecessary, FDA Says
Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review
GPhA And Actavis Divorcing: Biosimilars Behind The Rift
Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem
Biosimilar Suffix Naming Idea Trips On Dispensing Problem


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts